Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1292-1300

  Lalwani, Sanjay ^a   Chatterjee, Sukanta ^b   Chhatwal, Jugesh ^c   Simon, Anna ^d   Ravula, Sudheer ^e   Francois, Nancy ^f   Mehta, Shailesh ^e   Strezova, Ana ^g   Borys, Dorota ^f  

^a BHARATI VIDYAPEETH UNIVERSITY   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c CHRISTIAN MEDICAL COLLEGE   (India)

^d CHRISTIAN MEDICAL COLLEGE   (India)

^e GlaxoSmithKline Pharmaceuticals Ltd   (India)

^f GSK   (Belgium)

^g GlaxoSmithKline Pharmaceuticals ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VIRUS ANTIBODY; BACTERIUM ANTIBODY; OPSONIN; PHID-CV VACCINE;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BOOSTER DOSE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG SAFETY; EXPERIMENTAL STUDY; FEBRILE CONVULSION; FEMALE; GASTROENTERITIS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INDIA; MALE; MULTICENTER STUDY; NONTYPEABLE HAEMOPHILUS INFLUENZAE; NORMAL HUMAN; OPSONIZATION; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SKIN INFECTION; URINARY TRACT INFECTION; ADVERSE DRUG REACTION; ADVERSE EFFECTS; AGE; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; INFANT; PATHOLOGY; PHAGOCYTOSIS; PROCEDURES;

AGE FACTORS; ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INDIA; INFANT; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES;

EID: 84940329829     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00068-14     Document Type: Article

References (13)

1. Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. 2012. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum. Vaccin. Immunother. 8:612-622. http://dx.doi.org/10.4161/hv.19287.
2. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM. 2013. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 381:214-222. http://dx.doi.org/10.1016/S0140-6736(12) 61854-6.
3. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Carabajal C, Falaschi A, Calvo A, Wong D, Caicedo Y, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L. 2013. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against invasive pneumococcal disease in Latin America, abstr. 348. Abstr. 9th Int. Sympos. Antimicrob. Agents Resist. (ISAAR), Kuala Lumpur, Malaysia, 13 to 15 March 2013.
4. Tregnaghi M, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M. 2011. Evaluating the efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against com-munity- acquired pneumonia in Latin America, abstr. 411. Abstr. 29th Ann. Meet. Eur. Soc. Paediatr. Infect. Dis. (ESPID), The Hague, The Netherlands, 7 to 11 June 2011.
5. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Márquez V, Troitiño M, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Guiñazú JR, Ortega-Barría E, Yarzábal JP, Schuerman L. 2013. Eficacia de la vacuna neumocócica 10-valente conjugada a la proteína D del Haemophilus influenzae no tipificable (PHiDCV) contra neumonía adquirida en la comunidad en niños de Latinoamérica: un estudio controlado aleatorizado, abstr. OR-006. Abstr. 15th Congreso Latinoamericano de Infectiología Pediátrica (SLIPE), São Paulo, Brazil, 26 to 29 June 2013.
6. Sáez-Llorens X, Castrejón MM, Rowley S, Wong D, Calvo A, Rodriguez M, Troitiño M, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L. 2013. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama, abstr. 342. Abstr. 9th Int. Symp. Antimicrob. Agents Resist. (ISAAR), Kuala Lumpur, Malaysia, 13 to 15 March 2013.
7. Falagas ME, Zarkadoulia E. 2008. Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. Curr. Med. Res. Opin. 24:1719-1741. http://dx.doi.org/10.1185/ 03007990802085692. (Pubitemid 351929070)
8. Klugman KP, Madhi SA, Adegbola RA, Cutts F, Greenwood B, Hausdorff WP. 2011. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. Vaccine 29:3372-3373. http://dx.doi.org/10.1016/j.vaccine. 2011.02.089.
9. World Health Organization. 2012. Pneumococcal vaccines WHO position paper-2012. Wkly. Epidemiol. Rec. 87:129-144. http://www.who.int/wer/2012/ wer8714.pdf.
10. Poolman JT, Frasch CE, Käyhty H, Lestrate P, Madhi SA, Henckaerts I. 2010. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin. Vaccine Immunol. 17:134-142. http://dx.doi.org/10.1128/CVI. 00289-09.
11. Kim CH, Kim JS, Cha SH, Kim KN, Kim JD, Lee KY, Kim HM, Kim JH, Hyuk S, Hong JY, Park SE, Kim YK, Kim NH, Fanic A, Borys D, Ruiz-Guiñazù J, Moreira M, Schuerman L, Kim KH. 2011. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr. Infect. Dis. J. 30:e235- e243. http://dx.doi.org/10.1097/INF.0b013e31822a8541.
12. Lim FS, Chan PC, Chong CY, Yehudi YWS, Shafi F, Swinnen K, Hezareh M, Borys D. 2012. Antibody persistence after primary vaccination and immunogenicity, safety and reactogenicity of booster vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae proteinDconjugate vaccine in children in Singapore, abstr. PP26. Abstr. 14th Asia Pac. Congr. Pediatr. (APCP), Sarawak, Malaysia, 8 to 12 September 2012.
13. Kilpi T, Palmu AA, Puumalainen T, Nieminen H, Ruokokoski E, Rinta-Kokko H, Moreira M, Hezareh M, Borys D, Schuerman L, Jokinen J. 2013. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae proteinDconjugate vaccine (PHiD-CV10) against hospitaldiagnosed pneumonia in infants-FinIP Trial, abstr. 175. Abstr. 31st Ann. Meet. Eur. Soc. Paediatr. Infect. Dis. (ESPID), Milan, Italy, 28 May to 1 June 2013.